Evidence map›Paper›PMID 29589064›Full record

ReviewEuropean journal of clinical pharmacology2018

Recent major advances in cardiovascular pharmacotherapy.

James Milner, Andreia Cunha, Carlota Gamboa-Cruz, Julie Reis, Márcia Campos, Natália António

Abstract readReview
PubMed Publisher
In one paragraph

Review in European journal of clinical pharmacology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Observational
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

James MilnerCardiology Department, Coimbra Hospital and Universitary Centre, Coimbra, Portugal.
Andreia CunhaInstitute of Pharmacology and Therapeutics, Faculty of Medicine, University of Coimbra, Coimbra, Portugal.
Carlota Gamboa-CruzInstitute of Pharmacology and Therapeutics, Faculty of Medicine, University of Coimbra, Coimbra, Portugal.
Julie ReisInstitute of Pharmacology and Therapeutics, Faculty of Medicine, University of Coimbra, Coimbra, Portugal.
Márcia CamposInstitute of Pharmacology and Therapeutics, Faculty of Medicine, University of Coimbra, Coimbra, Portugal.
Natália AntónioCardiology Department, Coimbra Hospital and Universitary Centre, Coimbra, Portugal. natalia.antonio@gmail.com.ORCID http://orcid.org/0000-0003-3103-4353

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The field of cardiovascular pharmacotherapy remains extremely active. The aim of this review is to summarize the recent major advances in cardiovascular pharmacotherapy, with a focus on (1) the new approved drug for treatment of heart failure with reduced ejection fraction-sacubitril/valsartan; (2) proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors; (3) the novel reversal agents for non-vitamin K oral anticoagulants (NOACs); and finally, (4) new evidence on pharmacological treatment of coronary artery disease.

Indexed as

AminobutyratesAngiotensin Receptor AntagonistsBiphenyl CompoundsCardiovascular DiseasesDrug CombinationsHumansHypercholesterolemiaNeprilysinPCSK9 InhibitorsProprotein Convertase 9TetrazolesValsartanAminobutyratesAngiotensin Receptor AntagonistsBiphenyl CompoundsDrug CombinationsNeprilysinPCSK9 InhibitorsPCSK9 protein, humanProprotein Convertase 9sacubitril and valsartan sodium hydrate drug combinationTetrazolesValsartanAnticoagulation agentsAntidotesCardiovascular drugsCoronary artery diseaseHypercholesterolemiaSystolic heart failure

Identifiers

PMID29589064

What Socratic holds

Texttitle and abstract
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.